Clinical trials
for patients

This study is composed of 2 parts, part A and part B. The main objective of part A is to confirm whether the combination of the study drug with pembrolizumab is well tolerated and safe, and whether it helps treat people with CCECC. The main objective of Part B is to evaluate whether the combination of the study drug with pembrolizumab works better to treat people with CCECC than pembrolizumab alone.

The main objective of this study is to determine whether ZIM in monotherapy or together with DOM and in combination with chemotherapy is safe and effective when given to patients with the type of cancer you have. The first approved standard treatment for metastatic NSCLC that does not have gene changes is an anti-PD-(L)1 immunotherapy, which is a drug that helps the immune system target cancer cells for destruction, combined with or without platinum-based chemotherapy. The study will also try to...

The objective of this study is to analyze the safety and tolerability of the study drug, alone and in combination with ipilimumab, and to determine how it is processed by the body.

The main objective of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) and/or recommended dose for phase II (DRF2) of RO7247669 administered intravenously (IV) in monotherapy.

The objectives of this clinical trial are as follows: - To determine the response of CLL/LLCP patients to treatment with pyrtobrutinib (group A) compared to ibrutinib (group B). - Determine the duration of beneficial effects of treatment with the study drugs (including how long patients live). - Determine safety and tolerability in group A and group B. - Determine how patients in group A are doing compared to those in group B.

In this trial MK-1942 is being evaluated in people with mild to moderate dementia due to Alzheimer's disease. This trial is being conducted to: -Evaluate the safety of different doses of MK-1942. -Test the efficacy of different doses of MK-1942 compared to placebo.

The study is being conducted to answer the following questions: What is the highest dose of ART0380 that can be given together with a standard dose of gemcitabine to cancer patients without causing significant side effects (also known as the ¿recommended dose¿)? How often can the study products be given to cancer patients? What are the side effects of each of the study products? What are the side effects of the combination? How do the study products affect biomarkers? Can the study...

The objective of this study is to look at the efficacy and safety of an investigational antineoplastic drug called sitravatinib (also known as BGB-9468) in combination with tislelizumab (also known as BGB-A317) in subjects with non-small cell lung cancer/CPNM. This combination will be compared to the current chemotherapy available (docetaxel) to find out which is better or if it is equal.

The main objective of this clinical trial is to find out whether lurbinectedin administered in monotherapy or in combination with irinotecan (two different experimental groups, groups A and B) is superior to a control group (group C) consisting of topotecan or irinotecan in controlling the progression of small cell lung cancer (SCLC) in patients with progression after receiving a line of treatment with chemotherapeutics that included platinum salts. The knowledge gained from this treatment will ...